South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts College Of Medicine - Internal Medicine The TRANSLATE-ACS Study: Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Dr Beaver, B Eli Lilly 3,051.00 Events after Acute Coronary Syndrome A Phase III, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in Dr Burckhartt, B 6,283.00 Stable CHD Patients with a Documented Recent Acute Coronary Syndrome (ACS), Protocol No. NC20971 A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel- arm Trial to Determine Long-term Safety and Efficacy of Oral Dr Culpepper, M Otsuka Maryland Research Institute 34,745.00 Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease EVOLVE - Evaluation of Cinacalcet HCI Therapy to Lower Dr Culpepper, M 7,369.00 Cardiovascular Events Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimen in Subjects Dr Culpepper, M Otsuka Pharmaceutical 43,650.00 with Autosomal Dominant Polycystic Kidney Disease (ADPKD) A Phase 2, Multicenter, Randomized, Placebo-controlled, Double- Blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Dr Culpepper, M Otsuka Pharmaceutical 15,188.00 Immediate-release Formulations, in Subjects with Autosomal Dominant Polycystic Kidney Disease A Multi-center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Dr Culpepper, M Otsuka Pharmaceutical 2,000.00 Establish the Rate, Characteristics, and Determinants of Disease Progression A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate Dr Culpepper, M Rockwell Medical Technologies 20,681.00 SFP in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Treatments in Adult Subjects, Including the Elderly and Dr deMelo, S Braintree Laboratories 58,350.00 Subjects with Hepatic or Renal Insufficiency A Phase 2, Randomized, Double-Blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Dr Fagan, K Gilead Sciences 7,616.00 Pulmonary Arterial Hypertension A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Dr Fagan, K Gilead Sciences 6,125.00 Hypertension A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Dr Fagan, K United Therapeutics Corporation 6,406.00 Treated with Tyvaso (treprostinil) Inhalation Solution Drug Registry to PROSPECTively Describe Use of Room Temperature Stable Epoprostenol for Injection in Patients with Dr Fagan, K Actelion Pharmaceuticals US, Inc. 6,500.00 Pulmonary Arterial Hypertension Incidence of Secondary Iron Overload in Adults with Sickle Cell Disease (SCD) Following Chronic, Intermitten Red Blood Cell (RBC) Dr Haynes, J Novartis Pharmaceuticals 29,559.00 Transfusions A Phase III, Prospective, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of L-Glutamine Dr Haynes, J Emmaus Medical 2,769.00 Therapy for Sickle Cell Anemia and Sickle B-Thalassemia A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Dr Haynes, J HemaQuest Pharmaceuticals 12,500.00 Sickle Disease Long-term Follow-up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Dr Herrera, J Schering Plough Research Institute 15,395.00 Treatment of Chronic Hepatitis C South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts A Phase 3 Safety and Efficacy Study of Erythropoietin Use During Treatment of Subjects With Chronic Hepatitis C With Boceprevir, Dr Herrera, J Schering Plough Research Institute 7,103.00 Peginterferon Alpha-2b, and Ribavirin A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concommitantly with Dr Herrera, J Merck & Co., Inc. 61,596.00 Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection A Phase 3 , Active (Warfarin) Controlled, Randomized, Double- Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Dr Massey, C Bristol Myers-Squibb 6,655.00 Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation A Multicenter, Randomized, Double-Blind, Placebo-Controlled Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients withe a Recent Dr Omar, B Hoffman-La Roche, Inc 5,475.00 Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes M llit (T2D) #BC 22140 $ 359,016. College Of Medicine - 'Emergency Medicine An 8 Week, Randomized, Double-Blind, Parallel Group, Multi- Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination with Dr Pettyjohn, F Novartis Pharmaceuticals 18,906.00 Valsartan versus Valsartan Alone in Patients with Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus Distribution of PCV13 Serotype Streptococcus Pneumoniae in Adults 50 Years and Older Presenting to Selected US Hospitals with Chest X- Dr Pettyjohn, F Wyeth Pharmaceuticals 2,889.00 Ray Confirmed Community-Acquired Pneumonia A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo- Controlled Dose-Finding Study of Nifedipine GITS and Candesartan Dr Pettyjohn, F Bayer Healthcare Pharmaceuticals, Inc. 101,487.00 in Combination Compared to Monotherapy in Adult Patients with Essential Hypertension South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts A Multicenter, Randomized, Double-Blind, Placebo-Controlled 8 Week Study to Evaluate the Safety and Efficacy of Nebivolol and Dr Pettyjohn, F Forest Research Institute 115,189.00 Valsartan Given as a Fixed-Dose Combination in Patients with Stage 1 or Stage 2 Essential Hypertension Total Emergency Medicine College Of Medicine - Surgery A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Dr Brevard, S BHR Pharma LLC 4,500.00 Severe Traumatic Brain Injury Vascular Endothelium Changes After Surgery Dr Richards, WAmerican Society for Metabolic & Bariatric Surger 15,000.00 Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal Dr Rider, P Gore & Associates 11,200.00 and Coloanal Anastomoses Total Surgery College Of Medicine - Orthopaedic Surgery Trial to Evaluate Ultrasound in the Treatment of Tibial Fractures Dr. Alonso, J McMaster University 9,713.00 South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts Intranasal Ketorolac for Postoperative Pain after Total Knee and Shoulder Arthoplasty: A Prospective Randomized Trial Evaluating Dr Pearsall, A Luitpold Pharmaceuticals 29,975.00 Safety and Efficacy Total Orthopaedic Surgery College Of Medicine - Neurology A 24-Month Double-Blind, Randomized, Multicenter, Placebo- Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Dr Bassam, B Novartis Pharmaceuticals 25,487.00 Orally Once Daily Versus Placebo in Patients with Relapsing- Remitting Multiple Sclerosis Total Neurology dicine - ' diatrics A Multicenter, Prospective, Long-term, Observational Registry of Dr Crissinger, K Centocor, Inc. 41,025.00 Pediatric Patients with Inflammatory Bowel Disease Role of Inhaled Nitric Oxide in Modifying the Effects of Mechanical Ventilation with Supplemental Oxygen in Ureaplasma Exposed Dr Eyal, F 12,000.00 Newborn Rats An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tables in Opiod Experienced Children from Ages 6 to 16 Years Old, Inclusive with Dr Imran, H Purdue Pharma 10,528.00 Moderate to Severe Malignant and/or Nonmalignant Pain Requiring O i d A An Observational Prospective Study to Assess the Outcomes and Risk Factors of RSV Infection Among Premature Infants (32-35 Dr Savells, K MedImmune, LLC 6,813.00 weeks Gestational Age) Total Pediatrics South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts College Of Medicine - OBGYN SQNM-T21-202/Noninvasive Screening for Fetal Aneuploidy: A New Dr Baker, S Sequenom 12,859.00 Maternal Plasma Marker An Adaptive Multicentre, Randomized, Partially Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD/Efficacy Dr Lewis, D Novartis Pharmaceuticals 3,760.00 of RLX030 in Women with Pre-Eclampsia A Double Blind, Randomized, Controlled, Multicenter, Proof of Efficacy Study of Oral BGS649 vs. Placebo (Each Coadministered Dr Rizk, B Novartis Pharmaceuticals 24,379.00 with a Combined Oral Contraceptive) Assessing Pain Response in Patients with Refractory Endometriosis Total OBGYN College Of Medicine - Cell Biology & Neuroscience Effect of Hymovis/HYADD4-G on Viability and Function of Human Wilson, G Fidia Farmaceutici, S.p.A. 20,000.00 OA Chondrocytes Total Cell Biology & Neuroscience College Of Medicine - Physiology NovelMed 9405: Myocardial Infarction/Ischemia Reperfusion Injury Using Triphenyl Tetrazolium Chloride (TTC) in an Open Chest Dr Cohen, M NovelMed Therapeutics 8,000.00 Model with Rabbits Total Physiology South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts College Of Medicine - Microbiology Lion's/USA Eye Research Dr Lausch, R Lion'sClub 17,960.00 Microbiology USA Mitchell Cancer Institute An International Multi-Centre Open-Label 2-Arm Phase III Trial of Dr Butler, T Hoffmann-LaRoche 6,643.00 Adjuvant Bevacizumab in Triple Negative Breast Cancer A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab Dr Butler, T Novartis Pharmaceuticals 19,303.00 and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer An Open-Label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients Dr Cameron, D Alpha Oncology 7,250.00 with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) after First-Line Treatment with Bevacizumab Plus a Platinum Doublet-Containing Chemotherapy A Phase I/II , Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and Dr Clarkson, D Wyeth Research 108,006.00 ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Dr Finan, M Bristol-Myers Squibb 8,272.00 Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitadine (Vidaza) with the Nanoparticle Albumin Bound Dr Khong, H Abraxis/Celgene 81,125.00 Paclitaxel (Abraxane) in the Treatment of Patients with Advanced or Metastatic Solid Tumors and Breast Cancer South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts Prospective Evaluation of Cyberknife Sterotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR 3,200.00 Brachytherapy Dosimetry Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Dr Reed, E US Biotest 3,263.00 Patients Receiving Second-Line Combination of Gemcitabine and Platinum Therapy for Recurrent Ovarian Carcinoma A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Dr Reed, E Gilead Sciences 2,000.00 Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc. ChemoResponse Assay in Patients with Dr Rocconi, R Precision Therapeutics, Inc. 16,000.00 Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi- Center Study to Evaluate the Efficacy of Oral TKI258 as Second- Dr Rocconi, R Novartis Pharmaceuticals 5,750.00 Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients Dr Russo, S Celldex Therapeutics 6,000.00 with Newly Diagnozed, Surgically Resected, EGFRvIII-positive Glioblastoma An Open-Label Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitib as First-Line Followed by Second-Line Dr Taylor, W Novartis Pharmaceuticals 70,260.00 RAD001 in the Treatment of Patients with Metastatic Renal Cell C A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Hyperacute Pancreatic Cancer Vaccine in Subjects With Dr Taylor, W 18,544.00 Surgically Resected Pancreatic Cancer Total USAMCI South Alabama Medical Science Foundation Clinical Trials (Projects over $2,000) October 1, 2011 - September 30, 2012 | Project Responsible Source of Dept | Number Project Title Receipts $ 206,302.00
(The Memoirs of an Interesting and Unusual Girl)We've all heard how men and women are created equal; their journeys, however, are not. Occasionally there comes a life that spans the human condition. A life comedic, tragic, and compelling. A life spent in migration, character forged in pain, innocence dashed on misplaced trust. Hers is a life which she now views with humor, poignancy and meaning
PANÓPLIAS A morte de Tapir A Gonçalves DiasGuerreiraPara a Rainha Dona Amélia, de PortugalA um grande homem A sesta de Nero O Incêndio de Roma O sonho de Marco AntônioLendo a IlíadaMessalinaA ronda noturnaDelenda Carthago! A Morte de Tapir Uma coluna de ouro e púrpuras ondeantesSubia o firmamento. Acesos véus, radiantesRubras nuvens, do sol à viva luz, do poenteVinham, soltas, corre